The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Honey to Improve Sleep Quality

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04207281
Recruitment Status : Recruiting
First Posted : December 20, 2019
Last Update Posted : May 6, 2023
Sponsor:
Information provided by (Responsible Party):
Jane Alcorn, University of Saskatchewan

Tracking Information
First Submitted Date  ICMJE December 18, 2019
First Posted Date  ICMJE December 20, 2019
Last Update Posted Date May 6, 2023
Actual Study Start Date  ICMJE April 1, 2021
Estimated Primary Completion Date September 1, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 31, 2021)
Sleep quality as measured by Leeds Sleep Evaluation Questionnaire [ Time Frame: 14 days ]
Assessment of the quality of sleep as measured by a standardized tool, the Leeds Sleep Evaluation Questionnaire, which assesses subjective measures of sleep quality and amount, by the end of the 7 day intervention with the treatments (honey or comparator)
Original Primary Outcome Measures  ICMJE
 (submitted: December 18, 2019)
Sleep quality as measured by Leeds Sleep Evaluation Questionnaire [ Time Frame: 14 days ]
Assessment of the quality of sleep as measured by a standardized tool, the Leeds Sleep Evaluation Questionnaire, which assesses subjective measures of sleep quality and amount, by the end of the 7 day intervention with the treatments (honey or placebo)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 31, 2021)
  • Sleep quality as measured by daily sleep hygiene logs [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by a daily sleep hygiene log, which assesses subjective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or comparator)
  • Sleep quality as measured by daily morning sleep logs [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by a daily morning sleep log, which assesses subjective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or comparator)
  • Sleep quality as measured by actigraphy [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by actigraphy, which assesses objective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or comparator)
Original Secondary Outcome Measures  ICMJE
 (submitted: December 18, 2019)
  • Sleep quality as measured by daily sleep hygiene logs [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by a daily sleep hygiene log, which assesses subjective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or placebo)
  • Sleep quality as measured by daily morning sleep logs [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by a daily morning sleep log, which assesses subjective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or placebo)
  • Sleep quality as measured by actigraphy [ Time Frame: 14 days ]
    Assessment of the quality of sleep as measured by actigraphy, which assesses objective measures of sleep quality and amount by the end of the 7 day intervention with the treatments (honey or placebo)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Honey to Improve Sleep Quality
Official Title  ICMJE Honey to Improve Sleep Quality: a Randomized, Double-blind Trial
Brief Summary Inadequate sleep quality and duration affects quality of life, and can cause adverse health outcomes, for many Canadians. Existing sleep therapies have limitations, such as inability to adhere to a cognitive behaviour modification or the risk of dependence on pharmaceutical therapies. Raw honey has a long history of anecdotal reports supporting its use to improve sleep quality. In an effort to develop an evidence base for honey as a sleep aid, we completed a preliminary proof-of-principle study to assess feasibility and potential effectiveness of honey to improve sleep quality. Results of our preliminary study demonstrate that honey is safe and effective for improving quality of sleep with no associated adverse effects, as compared to melatonin. The current study design builds off the experiences of the preliminary trial and will add more scientific rigor to the evidence base we have started to build.
Detailed Description

Inadequate sleep quality and duration may result in adverse health outcomes and poorer quality of life. Research thus far identify interventions such as behavior modification and pharmaceuticals to aid sleep. According to Stats Canada (2007-2013 Canadian Health Measures Survey), despite these available interventions, roughly half of men and women (43% and 55%, respectively) aged 18-64 have difficulty falling or staying asleep; these results are similar to those reported in 2005. The lack of improvement in sleep might reflect important limitations with the current interventions; individuals with sleep disorders may find adherence to such interventions difficult to maintain (e.g. behavior modification) or the therapies may pose a risk (e.g. dependence on pharmaceuticals). There is a clear need for alternative therapeutic interventions, particularly those that are simple and cost effective.

Observational and anecdotal evidence supports honey as an alternative to promote better sleep. During sleep, the brain typically utilizes liver glycogen stores to provide continuous and adequate energy; foods that promote liver glycogen storage before sleep may ensure availability of this energy source and therefore lead to better sleep.4 Raw honey is a rapidly digestible and metabolizable dense energy source, and thus may provide this sleep time energy reserve. Additionally, honey may promote melatonin formation due to its possible tryptophan content (a precursor to melatonin) that both helps to initiate sleep as well as promote release of hormones that facilitate whole body recovery during sleep.

Based on this information, we completed a preliminary open-label proof-of-principle study to assess the feasibility and potential effectiveness of honey in improving sleep quality. In a cross-over study of poor sleepers, honey improved some areas of sleep compared to melatonin. The results of this study are the driving factor for the randomized, double-blind, cross-over study in poor sleepers proposed here.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Poor Quality Sleep
Intervention  ICMJE
  • Dietary Supplement: Raw Honey
    Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
  • Dietary Supplement: Comparator
    Honey comparator(1.5 tablespoons) administered for 7 days
Study Arms  ICMJE
  • Active Comparator: Honey
    Raw honey (1.5 tablespoons)
    Interventions:
    • Dietary Supplement: Raw Honey
    • Dietary Supplement: Comparator
  • Placebo Comparator: Comparator
    Honey comparator(1.5 tablespoons)
    Interventions:
    • Dietary Supplement: Raw Honey
    • Dietary Supplement: Comparator
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 18, 2019)
110
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 1, 2024
Estimated Primary Completion Date September 1, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Aged 18 - 55yrs
  • Male or female
  • Able to comply with study protocol and give informed consent
  • Healthy (no diagnosis of medical or mental illness and not suffering from vascular disease, diabetes mellitus, hyperlipidemia, obesity [body mass index over 30], dermatological disease, gynecological disease, endocrine disease)
  • Discontinuation of sleep aids 4 weeks in advance of the study
  • Self-report of having difficulty sleeping for 1 week or more

Exclusion Criteria:

  • Age: <18 and >55
  • Type I and Type II diabetes, current infectious disease (e.g. cold or flu)
  • Unstable medical condition
  • History of psychiatric disorder (past or present)
  • Pain syndrome affecting sleep
  • Obese (BMI over 30)
  • Pregnant or lactating women
  • Lifestyle habits that would modify the wake-sleep rhythm (e.g. night work; shift work; young children that interrupt sleep)
  • Substance and/or drug dependence (alcohol, nicotine, pain killers)
  • Use of the following medications during the study period: oral or injectable corticosteroid, sedating antihistamines (e.g. cold, allergy, motion sickness), psychotropic medications or hypnotics, benzodiazepine, narcotics, any illicit drugs
  • Use of stimulants (>4 cups [1 cup = 250 mL] of coffee/day)
  • Participation in any other clinical trial with an investigational agent within one month prior to randomization
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Whitney Duff, PhD 13069661852 whitney.duff@usask.ca
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04207281
Other Study ID Numbers  ICMJE Bio-1666
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Jane Alcorn, University of Saskatchewan
Original Responsible Party Jane Alcorn, University of Saskatchewan, PhD
Current Study Sponsor  ICMJE University of Saskatchewan
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jane Alcorn, PhD University of Saskatchewan
PRS Account University of Saskatchewan
Verification Date May 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP